ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

WSJ BLOG/Health: FDA Questions Benefit of Amgen Bone Drug in Certain Cases

(This story has been posted on The Wall Street Journal Online's Health Blog at http://blogs.wsj.com/health.) By Jennifer Corbett Dooren The Food and Drug Administration questioned the clinical benefit of using Amgen's bone drug Xgeva to prevent or delay the spread of prostate cancer to the bones. Xgeva is currently approved to delay fractures and other bone injuries in patients whose cancers have already spread to the bones. The company is seeking approval for use of Xgeva to prevent the spread of prostate cancer in a group of men that has not responded to other therapies. Xgeva will be reviewed Wednesday by the FDA's oncologic drugs advisory committee, which is made up of non-FDA medical experts. The FDA today posted a review of Xgeva in preparation for the meeting. Amgen conducted a study of Xgeva in 1432 men with prostate cancer that had not responded to previous therapies, but had not spread to the bones. Many types of cancer spread to the bones and cause tumors to grow, destroying the bone around the tumor, causing fractures and other problems. Half of the men were treated with Xgeva while the other half received a placebo. The study examined the time until men developed bone metastases or died, whichever occurred first. The study showed Xgeva prolonged median bone metastatis-free survival by 4.2 months compared to men in the placebo group. While the FDA said the study met its primary objective, the agency said it was unclear whether the results were "clinically meaningful" given that there was no difference in overall survival between the two patient groups. The agency said the risk-benefit ratio of Xgeva must also take into account the overall toxicity of the drug. One of the side-effects includes a risk of developing osteonecrosis of the jaw, or ONJ, a rare jaw-decay problem. Michael Severino, Amgen's vice president of research and development, said today that the company believes Xgeva does provide a clinically meaningful benefit because it delays the spread of cancer to the bone, which causes significant pain and other problems such as incontinence. Xgeva is also sold under the brand name Prolia as an osteoporosis treatment but is administered at a lower dose and less often than used to treat cancer-related bone complications. Xgeva and Prolia's combined sales in 2011 topped $550 million. The drugs target a protein called RANK Ligand, which helps regulate cells called osteoclasts that break down bone. (This post originally ran on Dow Jones Newswires.) -For continuously updated news from The Wall Street Journal, see WSJ.com at http://wsj.com.

Stock News for Amgen Inc. (AMGN)
DateTimeHeadline
07/06/201507:59:022 Dividend Stocks to Buy in a Market Crash
06/22/201501:03:00Celimmune to Present Experimental Anti-IL-15 Antibody AMG 714...
06/19/201516:00:00Amgen Presents Open-Label Extension Data From Ongoing Phase 2...
06/18/201517:32:35Amgen Vectibix Trial Promising in Patients With Colorectal Cancer
06/18/201516:01:00Results From Phase 3 Trial Show Vectibix® (Panitumumab) Improves...
06/17/201509:04:025 Healthcare Stocks for Dividend Lovers
06/15/201516:12:43Annual Report of Employee Stock Plans (11-k)
06/15/201516:10:32Annual Report of Employee Stock Plans (11-k)
06/14/201508:03:023 Big Healthcare Trends Wall Street Is Overlooking
06/11/201512:05:033 Things AbbVie Inc.'s Management Wants You to Know
06/10/201519:43:54FDA Advisory Panel Backs Amgen's Cholesterol-Lowering Drug Repatha...
06/10/201517:40:08FDA Panel Recommends Amgen Cholesterol Drug
06/10/201517:29:32FDA Panel Votes to Recommend Amgen Cholesterol Drug
06/10/201508:00:00Amgen To Discuss Details Of Repatha™ (Evolocumab) Biologics L...
06/09/201518:00:16FDA Panel Backs Cholesterol Drug, but Raises Concerns
06/09/201517:52:50FDA Panel Backs Cholesterol Drug, but Raises Concerns
06/09/201508:59:14Regeneron Halted Ahead of FDA Panel Review of Cholesterol Drug
06/08/201516:00:00Amgen To Present At The Goldman Sachs Global Healthcare Conference
06/08/201513:25:31Cholesterol Drugs: 3 Stocks to Watch This Week
06/07/201508:11:03These 3 Ultra-Rare Diseases Are Utterly Terrifying

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad